Novartis buys gene therapy company Arctos Medical By Reuters
ZURICH, (Reuters) – Novartis bought Arctos Medical, a gene therapy company that specialises in treating patients suffering from severe vision impairments. The Swiss firm announced Tuesday.
Novartis said the purchase, which was for an undisclosed price, demonstrates their commitment to optogenetics-based therapies that can restore vision to those with advanced blindness.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.